{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:59:17Z","timestamp":1771981157874,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38963-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:25:22Z","timestamp":1770326722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-340 improves the efficiency of p53 gene therapy in metastatic prostate cancer cells through downregulation of MDM2"],"prefix":"10.1038","volume":"16","author":[{"given":"Roham","family":"Deyhimfar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mousa","family":"Kehtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Saadatpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Nikoofar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Arshadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Dialameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Arefian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad Kazem","family":"Aghamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"3","key":"38963_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"issue":"10125","key":"38963_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C. et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391 (10125), 1023\u20131075 (2018).","journal-title":"Lancet"},{"issue":"2","key":"38963_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","volume":"15","author":"P Posdzich","year":"2023","unstructured":"Posdzich, P. et al. Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches. Cancers 15 (2), 461 (2023).","journal-title":"Cancers"},{"issue":"1\u20132","key":"38963_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14712598.2024.2311750","volume":"24","author":"AK Tsai","year":"2024","unstructured":"Tsai, A. K. et al. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert Opin. Biol. Ther. 24 (1\u20132), 51\u201362 (2024).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"38963_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","volume":"26","author":"S-E Al-Batran","year":"2015","unstructured":"Al-Batran, S-E. et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann. Oncol. 26 (6), 1244\u20131248 (2015).","journal-title":"Ann. Oncol."},{"issue":"1","key":"38963_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","volume":"8","author":"B Seruga","year":"2011","unstructured":"Seruga, B., Ocana, A. & Tannock, I. F. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Reviews Clin. Oncol. 8 (1), 12\u201323 (2011).","journal-title":"Nat. Reviews Clin. Oncol."},{"issue":"8","key":"38963_CR7","doi-asserted-by":"publisher","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","volume":"4","author":"AO Elmehrath","year":"2021","unstructured":"Elmehrath, A. O. et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw. Open. 4 (8), e2119568\u2013e (2021).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"38963_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei, H. E. et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 21 (1), 703 (2021).","journal-title":"Cancer Cell Int."},{"issue":"12","key":"38963_CR9","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.0.CO;2-V","volume":"83","author":"FJ Meyers","year":"1998","unstructured":"Meyers, F. J. et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer: Interdisciplinary Int. J. Am. Cancer Soc. 83 (12), 2534\u20132539 (1998).","journal-title":"Cancer: Interdisciplinary Int. J. Am. Cancer Soc."},{"issue":"7","key":"38963_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41416-019-0549-8","volume":"121","author":"DI Quinn","year":"2019","unstructured":"Quinn, D. I. et al. p53 nuclear accumulation as an early indicator of lethal prostate cancer. Br. J. Cancer. 121 (7), 578\u2013583 (2019).","journal-title":"Br. J. Cancer"},{"issue":"10","key":"38963_CR11","first-page":"1111","volume":"1","author":"JA Eastham","year":"1995","unstructured":"Eastham, J. A. et al. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Research: Official J. Am. Association Cancer Res. 1 (10), 1111\u20131118 (1995).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"issue":"8","key":"38963_CR12","doi-asserted-by":"publisher","first-page":"e3721","DOI":"10.1002\/jgm.3721","volume":"26","author":"SL Ginn","year":"2024","unstructured":"Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2023\u2014an update. J. Gene. Med. 26 (8), e3721 (2024).","journal-title":"J. Gene. Med."},{"issue":"4","key":"38963_CR13","doi-asserted-by":"publisher","first-page":"101155","DOI":"10.1016\/j.gendis.2023.101155","volume":"11","author":"L Qi","year":"2024","unstructured":"Qi, L. et al. Twenty years of Gendicine\u00ae rAd-p53 cancer gene therapy: the first-in-class human cancer gene therapy in the era of personalized oncology. Genes Dis. 11 (4), 101155 (2024).","journal-title":"Genes Dis."},{"issue":"7","key":"38963_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","volume":"127","author":"CP Martins","year":"2006","unstructured":"Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 (7), 1323\u20131334 (2006).","journal-title":"Cell"},{"key":"38963_CR15","doi-asserted-by":"crossref","unstructured":"Zhao, S. et al. USP38 functions as an oncoprotein by downregulating the p53 pathway through deubiquitination and stabilization of MDM2. Cell. Death Differ. 32, 1128\u20131141 (2025).","DOI":"10.1038\/s41418-025-01462-2"},{"issue":"1","key":"38963_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","volume":"19","author":"H Hou","year":"2019","unstructured":"Hou, H., Sun, D. & Zhang, X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 19 (1), 216 (2019).","journal-title":"Cancer Cell Int."},{"issue":"5","key":"38963_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/modpathol.3880330","volume":"14","author":"KR Leite","year":"2001","unstructured":"Leite, K. R. et al. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 14 (5), 428\u2013436 (2001).","journal-title":"Mod. Pathol."},{"issue":"8","key":"38963_CR18","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1021\/cr300362f","volume":"113","author":"H Dong","year":"2013","unstructured":"Dong, H. et al. MicroRNA: function, detection, and bioanalysis. Chem. Rev. 113 (8), 6207\u20136233 (2013).","journal-title":"Chem. Rev."},{"issue":"7","key":"38963_CR19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim, T. & Croce, C. M. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med. 55 (7), 1314\u20131321 (2023).","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"38963_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3892\/or.2015.4458","volume":"35","author":"K Huang","year":"2016","unstructured":"Huang, K., Tang, Y., He, L. & Dai, Y. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway. Oncol. Rep. 35 (2), 887\u2013895 (2016).","journal-title":"Oncol. Rep."},{"key":"38963_CR21","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1007\/s13277-015-4513-9","volume":"37","author":"S Mohammadi-Yeganeh","year":"2016","unstructured":"Mohammadi-Yeganeh, S. et al. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumor Biology. 37, 8993\u20139000 (2016).","journal-title":"Tumor Biology"},{"issue":"1","key":"38963_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7150\/ijbs.51123","volume":"17","author":"Z Huang","year":"2021","unstructured":"Huang, Z., Xu, Y., Wan, M., Zeng, X. & Wu, J. miR-340: A multifunctional role in human malignant diseases. Int. J. Biol. Sci. 17 (1), 236 (2021).","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"38963_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/pros.2990230206","volume":"23","author":"AG Carroll","year":"1993","unstructured":"Carroll, A. G., Voeller, H. J., Sugars, L. & Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23 (2), 123\u2013134 (1993).","journal-title":"Prostate"},{"issue":"3","key":"38963_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.gpb.2022.04.006","volume":"20","author":"F Xu","year":"2022","unstructured":"Xu, F. et al. DbDEMC 3.0: functional exploration of differentially expressed MiRNAs in cancers of human and model organisms. Genomics Proteom. Bioinf. 20 (3), 446\u2013454 (2022).","journal-title":"Genomics Proteom. Bioinf."},{"key":"38963_CR25","doi-asserted-by":"publisher","first-page":"e05005","DOI":"10.7554\/eLife.05005","volume":"4","author":"V Agarwal","year":"2015","unstructured":"Agarwal, V., Bell, G. W., Nam, J-W. & Bartel, D. P. Predicting effective MicroRNA target sites in mammalian mRNAs. Elife 4, e05005 (2015).","journal-title":"Elife"},{"issue":"1","key":"38963_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/biom13010159","volume":"13","author":"B Wallis","year":"2023","unstructured":"Wallis, B., Bowman, K. R., Lu, P. & Lim, C. S. The challenges and prospects of p53-Based therapies in ovarian cancer. Biomolecules 13 (1), 159 (2023).","journal-title":"Biomolecules"},{"issue":"5","key":"38963_CR27","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.3892\/ol.2016.5083","volume":"12","author":"S Chen","year":"2016","unstructured":"Chen, S. et al. Beside P53 and PTEN: identification of molecular alterations of the RAS\/MAPK and PI3K\/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets. Oncol. Lett. 12 (5), 3264\u20133272 (2016).","journal-title":"Oncol. Lett."},{"issue":"6817","key":"38963_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35051606","volume":"409","author":"MS Soengas","year":"2001","unstructured":"Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409 (6817), 207\u2013211 (2001).","journal-title":"Nature"},{"key":"38963_CR29","doi-asserted-by":"crossref","unstructured":"De Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proceedings of the National Academy of Sciences. ;99(5):2948-53. (2002).","DOI":"10.1073\/pnas.052713099"},{"issue":"13","key":"38963_CR30","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/sj.onc.1207396","volume":"23","author":"A Willis","year":"2004","unstructured":"Willis, A., Jung, E. J., Wakefield, T. & Chen, X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23 (13), 2330\u20132338 (2004).","journal-title":"Oncogene"},{"issue":"12","key":"38963_CR31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15384047.2016.1235655","volume":"17","author":"RE Tamura","year":"2016","unstructured":"Tamura, R. E., da Silva Soares, R. B., Costanzi-Strauss, E. & Strauss, B. E. Autoregulated expression of p53 from an adenoviral vector confers superior tumor Inhibition in a model of prostate carcinoma gene therapy. Cancer Biol. Ther. 17 (12), 1221\u20131230 (2016).","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"38963_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.gt.3300786","volume":"6","author":"A Vinyals","year":"1999","unstructured":"Vinyals, A. et al. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther. 6 (1), 22\u201333 (1999).","journal-title":"Gene Ther."},{"issue":"15","key":"38963_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1101\/gad.8.15.1739","volume":"8","author":"Y Barak","year":"1994","unstructured":"Barak, Y., Gottlieb, E., Juven-Gershon, T. & Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8 (15), 1739\u20131749 (1994).","journal-title":"Genes Dev."},{"issue":"6","key":"38963_CR34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/1541-7786.MCR-14-0089","volume":"12","author":"Q Li","year":"2014","unstructured":"Li, Q. et al. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol. Cancer Res. 12 (6), 901\u2013911 (2014).","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"38963_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C","volume":"45","author":"D Strohmeyer","year":"2000","unstructured":"Strohmeyer, D. et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45 (3), 216\u2013224 (2000).","journal-title":"Prostate"},{"issue":"6","key":"38963_CR36","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3892\/or.2014.3491","volume":"32","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. Fasudil inhibits prostate cancer-induced angiogenesis in vitro. Oncol. Rep. 32 (6), 2795\u20132802 (2014).","journal-title":"Oncol. Rep."},{"issue":"1","key":"38963_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yexcr.2014.08.002","volume":"328","author":"S Delle Monache","year":"2014","unstructured":"Delle Monache, S. et al. Src Inhibition potentiates antitumoral effect of Paclitaxel by blocking tumor-induced angiogenesis. Exp. Cell Res. 328 (1), 20\u201331 (2014).","journal-title":"Exp. Cell Res."},{"issue":"16","key":"38963_CR38","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.ejca.2010.07.021","volume":"46","author":"C Ortholan","year":"2010","unstructured":"Ortholan, C. et al. Bevacizumab\/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for Understanding the therapeutic effect of combined treatment. Eur. J. Cancer. 46 (16), 3022\u20133036 (2010).","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"38963_CR39","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00066-014-0708-z","volume":"190","author":"Y-H Chen","year":"2014","unstructured":"Chen, Y-H. et al. Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer. Strahlenther. Onkol. 190 (12), 1154 (2014).","journal-title":"Strahlenther. Onkol."},{"issue":"18","key":"38963_CR40","first-page":"6952","volume":"61","author":"S Pal","year":"2001","unstructured":"Pal, S., Datta, K. & Mukhopadhyay, D. Central role of p53 on regulation of vascular permeability factor\/vascular endothelial growth factor (VPF\/VEGF) expression in mammary carcinoma. Cancer Res. 61 (18), 6952\u20136957 (2001).","journal-title":"Cancer Res."},{"key":"38963_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10456-013-9376-3","volume":"17","author":"J Xiong","year":"2014","unstructured":"Xiong, J., Yang, Q., Li, J. & Zhou, S. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. Angiogenesis 17, 37\u201350 (2014).","journal-title":"Angiogenesis"},{"key":"38963_CR42","doi-asserted-by":"publisher","first-page":"155745","DOI":"10.1016\/j.cyto.2021.155745","volume":"149","author":"L Wu","year":"2022","unstructured":"Wu, L., Li, J., Zhao, F. & Xiang, Y. MiR-340-5p inhibits M\u00fcller cell activation and pro-inflammatory cytokine production by targeting BMP4 in experimental diabetic retinopathy. Cytokine 149, 155745 (2022).","journal-title":"Cytokine"},{"issue":"2","key":"38963_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/sj.cgt.7700009","volume":"6","author":"B Badie","year":"1999","unstructured":"Badie, B., Goh, C. S., Klaver, J., Herweijer, H. & Boothman, D. A. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 6 (2), 155\u2013162 (1999).","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"38963_CR44","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00018-016-2202-5","volume":"73","author":"Y Ying","year":"2016","unstructured":"Ying, Y. & Padanilam, B. J. Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D-overlapping pathways of regulated necrosis? Cell. Mol. Life Sci. 73 (11), 2309\u20132324 (2016).","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"38963_CR45","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/cdd.2013.52","volume":"20","author":"J Montero","year":"2013","unstructured":"Montero, J., Dutta, C., Van Bodegom, D., Weinstock, D. & Letai, A. p53 regulates a non-apoptotic death induced by ROS. Cell. Death Differ. 20 (11), 1465\u20131474 (2013).","journal-title":"Cell. Death Differ."},{"key":"38963_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/1477-3163.51368","volume":"8","author":"T Rabi","year":"2009","unstructured":"Rabi, T. & Bishayee, A. d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: generation of reactive oxygen species and induction of apoptosis. J. Carcinog. 8, 9 (2009).","journal-title":"J. Carcinog."},{"issue":"1","key":"38963_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbagen.2013.10.006","volume":"1840","author":"S Jayakumar","year":"2014","unstructured":"Jayakumar, S., Kunwar, A., Sandur, S. K., Pandey, B. N. & Chaubey, R. C. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim. Et Biophys. Acta (BBA)-General Subj. 1840 (1), 485\u2013494 (2014).","journal-title":"Biochim. Et Biophys. Acta (BBA)-General Subj."},{"issue":"1","key":"38963_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41434-019-0071-x","volume":"27","author":"RE Tamura","year":"2020","unstructured":"Tamura, R. E., Lana, M. G., Costanzi-Strauss, E. & Strauss, B. E. Combination of Cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth. Gene Ther. 27 (1), 15\u201326 (2020).","journal-title":"Gene Ther."},{"issue":"6","key":"38963_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/15665232113136660006","volume":"13","author":"M Rothe","year":"2013","unstructured":"Rothe, M., Modlich, U. & Schambach, A. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr. Gene Ther. 13 (6), 453\u2013468 (2013).","journal-title":"Curr. Gene Ther."},{"key":"38963_CR50","doi-asserted-by":"crossref","unstructured":"Xu, G., Pan, S., Zhu, Z. & Li, J. Overexpression of miR-340 inhibits cell proliferation and induces apoptosis of human bladder cancer via targeting Glut-1. BMC Urol. 21, 168 (2021).","DOI":"10.1186\/s12894-021-00935-z"},{"issue":"13","key":"38963_CR51","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1002\/cncr.25860","volume":"117","author":"Q Wu Zs, Wu","year":"2011","unstructured":"Wu Zs, Wu, Q. et al. miR-340 Inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c\u2010Met. Cancer 117 (13), 2842\u20132852 (2011).","journal-title":"Cancer"},{"issue":"1","key":"38963_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/dna.2015.3021","volume":"35","author":"P Wei","year":"2016","unstructured":"Wei, P. et al. microRNA-340 suppresses tumorigenic potential of prostate cancer cells by targeting high-mobility group nucleosome-binding domain 5. DNA Cell Biol. 35 (1), 33\u201343 (2016).","journal-title":"DNA Cell Biol."},{"issue":"3","key":"38963_CR53","first-page":"117","volume":"6","author":"MH Karimi","year":"2024","unstructured":"Karimi, M. H. scRNAseq, bulk-RNAseq and future deep learning RNAseq analysis: powerful prediction tools in prostate cancer therapy. Translational Res. Urol. 6 (3), 117\u2013119 (2024).","journal-title":"Translational Res. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38963-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:07:19Z","timestamp":1771978039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38963-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38963"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38963-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7527"}}